Koponen Mia E, Naray Emily, Hales Tim G, Forget Patrice
MSc Clinical Pharmacology, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom.
MSci Biomedical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom.
PLoS One. 2024 Dec 5;19(12):e0313749. doi: 10.1371/journal.pone.0313749. eCollection 2024.
To improve perioperative pain management, several interventions have been suggested for the prevention of increased pain sensitivity caused by opioids (called opioid-induced hyperalgesia). It is currently unclear which intervention is the most effective or appropriate in preventing opioid-induced hyperalgesia. Remifentanil is the most investigated opioid causing opioid-induced hyperalgesia. Thus, to guide future research, we conducted a systematic review and a network meta-analysis of preclinical trials investigating pharmacological interventions for remifentanil-induced hyperalgesia.
To identify relevant articles, electronic database searches were conducted in Embase, PubMed, Web of Science, and Google Scholar. Study characteristics were extracted, and the risk of bias was evaluated. Studies were included in the network meta-analysis if they shared similar characteristics with at least one other study. The interventions were ranked based on P-scores.
Overall, the 62 eligible trials tested 86 individual interventions and 6 combination interventions. Thirty-five studies eligible in the network meta-analysis formed five groups which were further divided into subgroups based on the quantitative sensory tests used. The best-ranked interventions within the subgroups were Anxa12-26, MRS2179, salicylaldehyde isonicotinoyl hydrazone (SIH), ANA-12, TDZD-8, ketamine, dexmedetomidine, JWH015, and the combination of KN93 and ketamine.
The current literature is too heterogeneous to produce a clear answer on which intervention is the most effective in preventing remifentanil-induced hyperalgesia. Future research in this field should prioritise finding the most effective intervention over testing the efficacy of new options. The results of our work can be used in planning which comparisons should be included in new trials.
为改善围手术期疼痛管理,已提出多种干预措施以预防由阿片类药物引起的疼痛敏感性增加(称为阿片类药物诱导的痛觉过敏)。目前尚不清楚哪种干预措施在预防阿片类药物诱导的痛觉过敏方面最有效或最合适。瑞芬太尼是引发阿片类药物诱导痛觉过敏研究最多的阿片类药物。因此,为指导未来研究,我们对研究瑞芬太尼诱导痛觉过敏的药理学干预措施的临床前试验进行了系统评价和网络荟萃分析。
为识别相关文章,我们在Embase、PubMed、Web of Science和谷歌学术中进行了电子数据库检索。提取了研究特征,并评估了偏倚风险。如果研究与至少一项其他研究具有相似特征,则纳入网络荟萃分析。根据P值对干预措施进行排名。
总体而言,62项符合条件的试验测试了86种单独干预措施和6种联合干预措施。网络荟萃分析中符合条件的35项研究形成了五组,根据所使用的定量感觉测试进一步分为亚组。亚组中排名最佳的干预措施是Anxa12 - 26、MRS2179、水杨醛异烟酰腙(SIH)、ANA - 12、TDZD - 8、氯胺酮、右美托咪定、JWH015以及KN93和氯胺酮的组合。
当前文献过于异质性,无法就哪种干预措施在预防瑞芬太尼诱导的痛觉过敏方面最有效给出明确答案。该领域未来研究应优先寻找最有效的干预措施,而非测试新选项的疗效。我们的研究结果可用于规划新试验应纳入哪些比较。